Abstract Radiation-induced glioma (RIG) is a uniformly fatal, treatment-resistant form of high-grade glioma that arises three years to several decades after cranial radiation therapy for previous pediatric cancers, commonly other pediatric brain tumors or leukemia. There is no standard-of-care or proven effective treatment for RIG. To better understand the clinical and biological features of RIG, including its response to treatment, we have established the Radiation-Induced Glioma Registry (RIG-R), as well as the RIG Research Consortium, a group of 25 investigators in 12 countries. All investigators and institutions are free to join the consortium and/or contribute patient data retrospectively to RIG-R on a collaborative basis. Data collection occurs via a REDCap survey, with funding available to support data extraction from medical records and data entry. Patient germline and tumor samples will also be collected if available. Data collected will include patient sociodemographics, history of the original tumor and treatment, latency to RIG development, RIG clinical and molecular characteristics, expanded RIG treatment information including specific medications/modalities, timing, and dosage, and patient outcomes. Our aim is to collect these data from 200 patients. When available, DNA sequencing will be performed on germline and tumor samples for correlation with treatment response and survival outcomes. We will then use Kaplan-Meier analysis and multivariable Cox proportional hazards to correlate demographic, biological, and treatment factors with RIG survival. RIG-R is now open following IRB clearance. Our overall goal is to combine findings from RIG-R with preclinical data from our patient-derived models to design a treatment protocol for the first RIG clinical trial. Investigators interested in joining the RIG Research Consortium and/or contributing to RIG-R can contact Dr. Green at adam.green@cuanschutz.edu.
Kaja et al. (Tue,) studied this question.